Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAU 2021 | Immune checkpoint inhibitors for BCG-resistant NMIBC

Cosimo De Nunzio • 1 Jul 2021
EAU 2021
Bladder Cancer Genitourinary Cancer BCG

Cosimo De Nunzio, MD, PhD, Sapienza University of Rome, Rome, Italy, comments on the role of immune checkpoint inhibitors for the treatment of Bacillus Calmette-Guérin (BCG)-resistant non muscle-invasive bladder cancer (NMIBC). This interview took place at the virtual European Association of Urology (EAU) Virtual Meeting 2021.

More from Cosimo De Nunzio

2:38
Real-world analysis of AEs associated with alpha blockers and drugs for mRCC
Cosimo De Nunzio • 1 Jul 2021
1:37
Preliminary safety results of the MITOBCG study in NMIBC
Cosimo De Nunzio • 1 Jul 2021

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals